Free tools Windows power users keep installed
One-click scans. No signup required.
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Total synthesis lets chemists build an antibiotic molecule from simpler starting materials instead of relying on the organism that naturally makes it. The resulting access to a molecule—and to deliberately varied versions of it—can help researchers study how structure affects antibacterial activity and explore ways to address resistance. It does not, by itself, establish that a candidate is safe, effective, manufacturable, or approved as a medicine.
How are scientists creating new antibiotics?
Antibiotic discovery can begin with a molecule found in nature, a known drug scaffold, or a newly designed structure. With total synthesis, chemists construct the complete target molecule from simpler chemical starting materials, without using its native biological production pathway. A practical route can make a complex molecule and related analogues available for systematic study, an approach discussed by chemists Andrew G. Myers, Seth B. Herzon, and Scott J. Miller in a 2014 review of antibiotic synthesis.
Researchers can then ask whether changing part of a molecule alters its ability to reach a bacterial target, bind it, or retain activity against resistant bacteria. This is structure–activity research: it helps scientists test design ideas, but a promising result in a lab assay or animal model remains an early finding, not proof of a useful human drug.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallOutdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchWhy make a molecule synthetically instead of relying on microbes?
Some antibiotics are produced by microorganisms, but obtaining enough of a complex natural product—or making planned structural changes to it—can be difficult. Chemical synthesis can provide access to a target and its analogues for structural and biological experiments. Biosynthesis, meanwhile, offers a way to study or potentially improve the organism’s own production process. These are complementary research routes, not universally competing solutions.
#1 Best Overall
| Research question | Chemical synthesis | Biosynthesis or pathway engineering |
|---|---|---|
| Can researchers access or diversify the target structure? | A designed synthetic route may enable construction of the target and analogues; the practical difficulty depends on the molecule. | Researchers can investigate or engineer the biological pathway, but the cited odilorhabdin report focuses on understanding its biosynthesis and potential production improvement. |
| Can it supply material for study? | A workable route can provide material for structural and biological studies. The cited sources do not give a comparable amount or yield across the examples. | Microbial output may be limited; the odilorhabdin study was motivated in part by low yields. |
| What are the technical challenges? | Complex stereochemistry and construction of macrocycles can make synthesis demanding. | Researchers must understand and potentially modify the organism’s production pathway. |
| Which route is cheaper or scales better? | The cited sources provide no head-to-head economic or yield comparison, so they do not support a universal ranking. | |
The choice depends on the molecule, the research goal, and whether a route can deliver useful quantities and variants. A pathway study can also reveal how a natural product is assembled without first requiring the whole product in hand: that was the advantage described by team leader Helge Bode in the Max Planck Society’s June 2024 account of odilorhabdin biosynthesis.
What does cresomycin show?
Cresomycin is a fully synthetic candidate inspired by lincosamide antibiotics. NIH’s March 12, 2024 report says researchers used knowledge of antibiotic structures and ribosome binding to design the compound. Ribosomes make proteins, and bacterial ribosomes are established antibiotic targets. The report described cresomycin activity against gram-positive and gram-negative bacteria, including resistant strains, as well as experiments in mice.
What the mouse result means—and does not mean
In one reported experiment involving a lethal resistant Staphylococcus aureus infection, all 10 mice treated with cresomycin survived for seven days; 9 of 10 untreated mice died within two days. This is an animal result from a specific experiment, not evidence of a human survival benefit. At the time NIH published its report, the candidate had not been tested in people. Andrew Myers, identified by NIH as a Harvard University researcher, cautioned: “We don’t yet know whether cresomycin and drugs like it are safe and effective in humans.”
How are researchers synthesizing other antibiotic candidates?
Peptide antibiotics provide other examples of chemical synthesis and analogue research. A May 2024 bulletin from the University of Hong Kong reported that its group had achieved total synthesis of teixobactin and Malacidin A, and had prepared more than 100 teixobactin analogues. The same bulletin said Kynomycin had been approved for clinical trials in mainland China at that time. That statement is specific to the bulletin’s date and location; it is not a current trial-registry status check.
These examples show how synthesis can support access to complex antibiotic structures and the systematic preparation of variants. They do not establish that every analogue is active, that any named candidate will become a medicine, or that synthetic production will be the eventual manufacturing route.
Can synthetic chemistry help overcome antibiotic resistance?
It can help researchers investigate that possibility. Chemists can alter a scaffold and test whether the changes affect activity against resistant bacteria or interactions with a bacterial target. Cresomycin illustrates this research logic: its design drew on structural knowledge of lincosamides and ribosome binding, and NIH’s 2024 report described activity against resistant strains in preclinical work.
Rank #4
Resistance is not solved by making a molecule alone. A candidate must still demonstrate appropriate activity, safety, and efficacy in human studies, and it must be produced reliably at practical scale. The sources cited here do not establish those outcomes for cresomycin, teixobactin, Malacidin A, or Kynomycin.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problemsWhat remains before a synthesized antibiotic can become a treatment?
Synthesis is an enabling step in discovery and research, not a substitute for drug development. Before a candidate could be used as a treatment, its developers would need to establish whether it works safely in people, determine how it should be used, show that it can be manufactured consistently, and meet applicable regulatory requirements. Laboratory or animal activity can justify further investigation, but it cannot answer those later questions.
For that reason, the most defensible claim is also the useful one: total synthesis expands what researchers can build and study. Whether any particular molecule becomes an antibiotic medicine depends on evidence beyond the act of synthesis.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
